Pfizer Inc. (PFE) Thursday said the company and DxS, a wholly owned subsidiary of QIAGEN N.V. (QGEN) reached an agreement to develop a companion diagnostic test kit for PF-04948568, an immunotherapy vaccine in development for the treatment of glioblastoma multiforme. Financial terms of the diagnostic agreement have not been disclosed. The EGFRvIII companion diagnostic would be developed and manufactured at QIAGEN's Center of Excellence for Companion Diagnostics in Manchester, UK.
Glioblastoma multiforme is the most common malignant primary brain tumor in adults and occurs in around 25,000 patients worldwide each year.
For comments and feedback contact: editorial@rttnews.com
June 05, 2026 16:18 ET A busy week for economic news flow saw a slew of reports being released that reflected the trends in the U.S. labor market. In Europe, economic growth and inflation data gained attention as the European Central Bank and Bank of England head for policy session later in the month. In Asia, the monetary policy session of the Indian central bank was in focus as the country, a major oil importer, reels under the pressures of a weaker rupee and rising inflation.